Novo Nordisk (NOVOB DC) to cut Ozempic and Wegovy prices by up to 50% starting January 2027, according to WSJ; WeGovy and Ozempic will list for USD 675/month

Novo Nordisk (NOVOB DC) to cut Ozempic and Wegovy prices by up to 50% starting January 2027, according to WSJ; WeGovy and Ozempic will list for USD 675/month.

Novo Nordisk's decision to cut prices on Ozempic and Wegovy by up to 50% signals a strategic move aimed at increasing market share and addressing competitive pressures from companies like Eli Lilly. This pricing shift, effective in January 2027, could enhance accessibility to these blockbuster drugs, potentially impacting revenue projections and shareholder sentiment as investors assess the long-term implications for the pharmaceutical sector.